Armistice Capital’s Avalo Therapeutics AVTX Stock Holding History

Quarter	Market Value	Status	Shares	Shares Change %	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,415,000	Closed	-$7.73M	–	224
2023 Q1	$7.73M	Buy	4,415,000 +450,334	+11%	+$788K	0.11%	96
2022 Q4	$20M	Hold	3,964,666	–	–	0.35%	51
2022 Q3	$13.2M	Sell	3,964,666 -43,611,334	-92%	-$145M	0.23%	65
2022 Q2	$23.8K	Hold	47,576,000	–	–	0.42%	56
2022 Q1	$34.5M	Buy	47,576,000 +2,576,000	+6%	+$1.87M	0.67%	43
2021 Q4	$76.5M	Hold	45,000,000	–	–	1.25%	14
2021 Q3	$98.1M	Buy	45,000,000 +5,900,000	+15%	+$12.9M	1.66%	9
2021 Q2	$128M	Buy	39,100,000 +6,465,715	+20%	+$21.1M	2.29%	1
2021 Q1	$98.6M	Buy	32,634,285 +2,500,000	+8%	+$7.55M	2.26%	1
2020 Q4	$79.6M	Buy	30,134,285 +120,000	+0.4%	+$317K	2.71%	1
2020 Q3	$68.3M	Buy	30,014,285 +100,000	+0.3%	+$227K	2.48%	1
2020 Q2	$77.8M	Buy	29,914,285 +1,753,680	+6%	+$4.56M	3.41%	1
2020 Q1	$69.8M	Buy	28,160,605 +7,477,372	+36%	+$18.5M	4.32%	1
2019 Q4	$111M	Hold	20,683,233	–	–	6.43%	1
2019 Q3	$68M	Buy	20,683,233 +2,253,948	+12%	+$7.42M	4.51%	1
2019 Q2	$100M	Buy	18,429,285 +125,000	+0.7%	+$680K	6.32%	1
2019 Q1	$107M	Buy	18,304,285 +175,486	+1%	+$1.02M	5.85%	1
2018 Q4	$58.6M	Buy	18,128,799 +628,399	+4%	+$2.03M	4.44%	2
2018 Q3	$81.7M	Buy	17,500,400 +1,086,000	+7%	+$5.07M	4.91%	1
2018 Q2	$71.2M	Buy	16,414,400 +364,400	+2%	+$1.58M	4.65%	1
2018 Q1	$68.9M	Hold	16,050,000	–	–	5.27%	1
2017 Q4	$51.4M	Buy	16,050,000 +50,000	+0.3%	+$160K	5.12%	1
2017 Q3	$13.6M	Buy	16,000,000 +12,615,776	+373%	+$10.7M	1.6%	16
2017 Q2	$1.94M	Buy	+3,384,224	New	+$1.94M	0.25%	50